ARGX 119
Alternative Names: ARGX-119Latest Information Update: 18 Apr 2025
At a glance
- Originator argenx
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action MUSK protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
- Phase I Congenital myasthenic syndromes
Most Recent Events
- 08 Apr 2025 Adverse events data from a phase I trial in Congenital myasthenic syndromes released by argenx
- 13 Jan 2025 argenx plans a phase II proof-of-concept trial for Spinal muscular atrophy (IV) in 2025
- 23 Oct 2024 Phase-II clinical trials in Amyotrophic lateral sclerosis in Sweden, Denmark, Canada, Belgium (IV) (NCT06441682)